Afghanistan, Aug. 27 -- The European Commission has approved Gilead's lenacapavir, a twice-yearly HIV prevention injection, offering high-risk individuals a long-acting alternative and expanding access across Europe and low-income countries.
The European Commission has granted marketing authorization for Gilead Sciences' lenacapavir, a twice-yearly injection aimed at preventing HIV infection. Branded as Yeytuo in Europe, the drug is intended for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV among high-risk adults and adolescents.
Lenacapavir has demonstrated nearly 100% effectiveness in large clinical trials, offering a long-acting alternative to daily oral medications. The World Health Organization recommend...